GlaxoSmithKline Pharmaceuticals Limited announces results for the quarter ended June 30, 2020

GlaxoSmithKline Pharmaceuticals Limited today declared its f inancial results f or the quarter ended 30th June 2020. Revenue for the quarter came in at Rs.649 crores. Profit After Tax at Rs 111 crores recorded a growth of 3%.

Commenting on the results, Sridhar Venkatesh, Managing Director, GlaxoSmithKline Pharmaceuticals Limited said,

We demonstrated extreme resilience in the f ace of the unprecedented business environment created by the Covid-19 pandemic. While keeping employee saf ety and well-being as our topmost concern and remaining committed to patients’ access to medicines, we were the first multi-national company to get back to the f ield once the lockdown restrictions were lif ted by the government. It is encouraging f or us to note that during such challenging times our market share has grown despite the established brands not perf orming up to our expectations due to prevailing market conditions. The FY21 is a promising year for GSK as we are set to introduce new assets and these launches, as it happens post regulatory approvals, shall contribute to GSK firming its position as a science- and innovation-led biopharmaceutical company.

Sridhar Venkatesh,

Managing Director, GlaxoSmithKline Pharmaceuticals Limited

About GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies, committed to improving the quality of human life by enabling people to do more, f eel better and live longer. For more information, visit

Media Contacts:

Ransom D’Souza
Vice President Corporate Communications and Government Affairs
Tel: +91 22 24959203